Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment

KYOUNG SOO KIM¹, HYUN-MI CHOI¹, HYE-IN JI¹, RAN SONG², HYUNG-IN YANG², SOO-KON LEE³, MYUNG CHUL YOO¹ and YONG-BEOM PARK³

¹East-West Bone and Joint Research Institute, Kyung Hee University Hospital at Gangdong, Kyung Hee University; ²Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University Medical School, Gangdong-gu; ³Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemoon-gu, Seoul, Republic of Korea

Received April 28, 2012; Accepted October 17, 2013
DOI: 10.3892/mmr.2013.1764

Abstract. The aim of this study was to determine whether disease activity and the type of therapy differentially modulate serum adipokine levels in patients with rheumatoid arthritis (RA), and whether pre-therapy adipokine levels contribute to resistance to treatment. Fasting blood samples from 40 RA patients were obtained at baseline and six months following therapeutic treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of adiponectin, leptin, visfatin and resistin were measured by ELISA. Baseline adipokine levels did not exhibit a statistically significant difference when comparing patients with moderate and high disease activity, based on the disease activity score in 28 joints (DAS28). Of all the adipokines, only adiponectin was significantly increased in patients responding to DMARDs and/or TNF-α blocker therapy, based on the American College of Rheumatology 20% improvement criteria (ACR20) at six months (2,964±1,237 to 3,683±1,511 ng/ml, P<0.01). However, adiponectin levels in non-responders did not significantly increase (3,192±2,090 to 3,222±1,150 ng/ml). By contrast, there were no statistically significant changes in leptin, resistin or visfatin levels in either the responders or non-responders. Serum adipokine (adiponectin, leptin, visfatin, and resistin) levels in RA patients did not significantly change following therapy, with the exception of adiponectin. Adipokine levels may not contribute to therapeutic resistance to DMARDs and/or TNF-α blocking agents.

Introduction

White adipose tissue (WAT) was, until recently, only regarded as a predominant site of energy storage with important roles in the control of energy homeostasis. However, WAT is now considered to be a predominant endocrine organ in humans, secreting a wide range of biologically active molecules, including numerous adipokines (1). A number of these adipokines, which are predominantly produced by WAT, exhibit potent modulatory effects on target tissues and cells involved in inflammation and immunity. These include leptin, adiponectin, visfatin and resistin.

Adipokine levels are elevated in the sera and synovial fluids of patients with rheumatoid arthritis (RA). This suggests that adipokines are involved in the pathogenesis of RA by exerting potent modulatory effects on target tissues and cells involved in rheumatic disease, including cartilage, synovium, bone, and various immune cells (4,5). Adiponectin also induces the in vitro production of pro-inflammatory cytokines, including interleukin (IL)-6, matrix metalloproteinase (MMP)-1 and IL-8 from RA synovial fibroblasts (6,7). Thus, adiponectin is hypothesized to exert significant pro-inflammatory and matrix-degrading effects. Leptin stimulates T cell-mediated immunity, cytokine release from monocytes/macrophages and the differentiation of hematopoietic cells (8). Visfatin is a novel mediator of innate immunity. It is key in the persistence of inflammation through its capacity to inhibit neutrophil apoptosis (9). Furthermore, visfatin activates transcription factors, including nuclear factor (NF)-κB and activator protein (AP)-1 and induces the production of IL-6, IL-8, MMP-1 and MMP-3 in RA synovial fibroblasts and IL-6 and tumor necrosis factor (TNF) in monocytes (10).
Human resistin also has pro-inflammatory functions, including the activation of NF-κB-dependent pathways to produce TNF-α, IL-6 and IL-1β in human peripheral blood mononuclear cells (11). It is widely accepted, that adipokines are important in the pathogenesis of RA, yet the in vivo role of adipokines and their association with disease activity is poorly understood. Additional insight into the role of adipokines may aid in the development of novel therapeutic agents. In this study, the modulation of serum adipokines (adiponectin, leptin, resistin and visfatin) was evaluated depending on RA disease activity or the type of therapy, including disease-modifying antirheumatic drugs (DMARDs) and TNF-α blockers.

Patients and methods

Patients. A total of 40 RA patients (32 females and 8 males; mean age ± SD, 45.2±13.6 years), who fulfilled the 1987 revised criteria of the American College of Rheumatology (ACR) for RA (12), were evaluated prior to and six months following RA therapy (Table I). All the patients were consecutively admitted to the outpatient clinic of the Rheumatology Division of the Yonsei University Hospital (Seoul, Korea) and were treated with DMARDs: Monotherapy or combination therapy with methotrexate, sulfasalazine and hydroxychloroquine. In addition, 16 patients were also treated with TNF-α blockers [such as etanercept (Enbrel®; Pfizer, New York, NY, USA), infliximab (Remicade®; Janssen Biotech, Horsham, PA, USA), adalimumab (Humira®; Abbott Laboratories, Chicago, IL, USA)]. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) were measured at the baseline. Disease activity was assessed according to the disease activity score in 28 joints (DAS28) based on C-reactive protein level (CRP) at baseline and six months following treatment (13). Health-related quality of life was evaluated using the patient-reported Health Assessment Questionnaire disability index (HAQ DI) (14). The therapeutic response was evaluated six months following treatment, according to the ACR response criteria (15). Patients were categorized as responders or non-responders, on the basis of fulfilling the ACR 20% improvement criteria (achieving an ACR20 response) six months following treatment. Serum samples were collected prior to (baseline) and six months following therapy. The present study was conducted in accordance with the recommendations of the Declaration of Helsinki and was approved by the Institutional Review Board of the Yonsei University Hospital. All the patients provided written informed consent.

Measurement of serum adipokine levels by ELISA. For the assessment of adiponectin, leptin, resistin and visfatin levels in serum, the serum was diluted with diluent buffer (BD OptEIA; BD Bioscience, San Diego, CA, US) for the proper detection range with ELISA, according to the manufacturer’s protocol. The adipokine levels in serum were measured using a commercial ELISA kit. Adiponectin and leptin ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). Resistin and visfatin ELISA kits were purchased from MilliPore (Billerica, MA, USA) and BioVision (Mountain View, CA, USA), respectively.

Statistical analysis. Serum adipokine levels at baseline DAS28 were compared using the Mann-Whitney U test (two-tailed). Pre- and post-treatment levels were compared using a Wilcoxon signed rank test (two-tailed). Data are expressed as the mean ± SD. The differences between the groups were compared using the Mann-Whitney U test (two-tailed). Prism software 4 (Graphpad Software, San Diego, CA, USA) was used for statistical analysis and graphing. P<0.05 was considered to indicate a statistically significant difference.

Results

Baseline demographics and clinical characteristics. As shown in Table I, the majority of patients were female and had active disease (DAS28 mean ± SD, 5.38±1.0) prior to therapy. Patients were recently diagnosed with RA, having a mean disease duration of 5.2 months. Following DMARD and/or TNF-α blocker therapy, 30 (75%) patients were responders and 10 (25%) were non-responders. Of the responders, 15 were treated with DMARDs only, whereas another 15 were treated with DMARDs followed by a TNF-α blocker. Baseline demographics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All RA patients</th>
<th>Responders</th>
<th>Non-responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n (%)</td>
<td>40</td>
<td>30 (75)</td>
<td>10 (25)</td>
</tr>
<tr>
<td>Mean age ± SD (years)</td>
<td>45.2±13.6</td>
<td>45.4±14.2</td>
<td>44.5±12.2</td>
</tr>
<tr>
<td>Gender (female/male)</td>
<td>32/8</td>
<td>24/6</td>
<td>8/2</td>
</tr>
<tr>
<td>Disease duration, months (range)</td>
<td>5.2 (1-12)</td>
<td>5.5 (1-12)</td>
<td>4.6 (2-8)</td>
</tr>
<tr>
<td>RF-positive, n (%)</td>
<td>38 (95)</td>
<td>28 (93)</td>
<td>10 (100)</td>
</tr>
<tr>
<td>Anti-CCP positive, n (%)</td>
<td>36 (90)</td>
<td>27 (90)</td>
<td>9 (90)</td>
</tr>
<tr>
<td>Baseline DAS28 score</td>
<td>5.38±1.0</td>
<td>5.65±0.9</td>
<td>4.54±0.7</td>
</tr>
<tr>
<td>HAQ-DI score</td>
<td>0.96±0.5</td>
<td>1.03±0.5</td>
<td>0.75±0.6</td>
</tr>
<tr>
<td>Anti-TNF-α blocker use, n (%)</td>
<td>16 (40)</td>
<td>15 (50)</td>
<td>1 (10)</td>
</tr>
</tbody>
</table>

*P<0.05, compared with non-responders. RA, rheumatoid arthritis; n, number of subjects; SD, standard deviation; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score in 28 joints; HAQ-DI, Health Assessment Questionnaire disability index; TNF-α, tumor necrosis factor-α.
and clinical characteristics were similar between responders and non-responders, with the exception of the baseline DAS28 score, which was significantly higher in the 30 responders than in the 10 non-responders (5.65±0.9 vs. 4.54±0.7; P<0.05). Due to a relatively higher disease activity, a greater number of patients in the responder group received TNF-α blocker therapy compared with the non-responder group.

Effect of disease activity on serum adipokine levels. To determine how adipokine levels are regulated in patients with RA depending on disease activity, serum was collected prior to (at baseline) and six months following therapy. Adipokine levels in the sera of patients with moderate disease activity on the basis of DAS28 were not significantly different from that of patients with high disease activity (Fig. 1). Thus, the
change in serum adipokine levels prior to and following the therapeutic treatment of patients, who responded well to DMARD and/or TNF-α blocker treatment in terms of ACR20 was examined (Fig. 2). Adiponectin levels were significantly elevated in responders subsequent to treatment (mean ± SD; from 2,964±1,237 to 3,683±1,511 ng/ml, P=0.001), while adiponectin levels in non-responders revealed no statistically significant difference (3,192±2,090 to 3,222±1,150). By contrast, leptin, resistin and visfatin levels were not significantly changed in either responders or non-responders.

**Effect of the type of therapeutic agent on serum adipokine levels.** To determine whether the type of therapeutic agent differentially affects adipokine levels, the responder group was subdivided into patients receiving only DMARDs and patients treated with DMARDs followed by TNF-α blockers (Fig. 3). Adiponectin levels in the DMARD only group (3,008±1,209 to 4,089±1,345 ng/ml) showed a greater increase compared with those of the DMARD+TNF-α blocker group (2,921±1,305 to 3,278±1,603 ng/ml) following treatment, while other adipokine levels were not significantly affected.

**Effect of pre-treatment adipokine levels on resistance to treatment.** The effect of pre-treatment adipokine levels on resistance to treatment was also investigated. No statistically significant difference was identified in adipokine levels at baseline between responders and non-responders, suggesting that the responsiveness to therapeutic treatments was not affected by adipokine levels (data not shown).

**Discussion**

In this study, the effects of RA disease activity and type of therapeutic agent on serum adipokine levels was evaluated, as well as the correlation between pre-treatment adipokine levels and resistance to treatment. It was observed that only the level of adiponectin was significantly increased following therapeutic treatment, while other adipokine levels were not identified to be significantly different. Increased adiponectin was observed in patients treated with DMARDs alone or with a combination of DMARDs and TNF-α blockers. However, the level of adipokines at baseline was not significantly different between patients with moderate versus high disease activity. This suggests that moderate versus high RA disease activity does not significantly affect adipokine expression, as the two patient groups exhibited significant in vivo inflammation at baseline.

Previous studies have demonstrated that adipokine levels are affected by disease activity. DMARD treatment increased serum adiponectin levels in RA patients (16). TNF-α blocker therapy also increased adiponectin levels in a female RA patient three months following treatment (17). Other studies have shown that anti-TNF-α therapy significantly increases serum adiponectin levels two and six weeks following therapy in RA patients (18). Contradictory to these results, another study reported that a short- or long-term TNF-α blockade alone had no affect on circulating leptin and adiponectin concentrations in RA patients, while patients treated with anti-TNF-α and concomitant corticosteroids on a regular basis demonstrated a significant decrease in adiponectin levels six months after therapy (19). Furthermore, visfatin was not associated with inflammation in patients with severe RA undergoing anti-TNF-α therapy (20). Another study reported that anti-TNF-α therapy resulted in a rapid reduction in serum resistin levels, but did not modulate leptin levels in RA patients (21). It was also demonstrated that serum leptin concentrations are inversely correlated with inflammation in RA (22). The increased adipokine levels post-treatment in these studies...
is concurrent with the results of the present study; however, in order to clarify data concerning additional adipokines, further studies are required. Thus, it is currently difficult to delineate the behavior of these adipokines during the course of the disease or the way in which they are affected by treatment. In line with this, the resistin level in the serum and joint fluid of patients with RA was significantly higher compared with that in osteoarthritis (OA) patients (23). Serum adiponectin levels in RA patients were higher than those observed in the healthy controls, although not significantly different from those of OA patients (24). Serum adiponectin levels in RA patients were significantly lower compared with the synovial fluid levels, regardless of increased local inflammation in the joint. A previous study has demonstrated that serum adiponectin levels in RA patients are higher compared with OA patients, which is contradictory to the findings mentioned previously, stating that decreased disease activity or inflammation increases serum adiponectin levels. In addition, leptin levels in the joint fluid of patients with OA were significantly higher than the serum levels (23).

Certain criticisms may be raised regarding the parameters used for disease activity. In this study, the correlation analysis focused on DAS28 and additional parameters were not compared systematically. DAS28 may not be an ideal parameter to analyze disease activity over time. It is usually accepted that DAS28 is not an ideal parameter as it only focus on 28 joints excluding foot joints. Also, it focus on disease activity but not radiographic damage. Thus, doctors still require more developed parameters to evaluate disease degree. Thus, DAS28 in combination with analysis of radiographic damage and other parameters may be a useful application of adipokine levels with regard to disease progression. Furthermore, additional parameters to consider include: Age, body mass index (BMI) (with/without normalization), disease duration, CRP, association with RF/anti-CCP, proinflammatory cytokines, radiographic damage and gender. Leptin levels demonstrate statistically significant gender-specific differences (23), while adiponectin is unrelated to age, disease duration, BMI or disease activity in RA patients (24). In addition, systemic values of metabolically relevant factors, such as adipokines, may not reflect the situation in a specific organ or tissue under pathophysiological conditions, including the joint.

Adiponectin with low molecular weight has anti-inflammatory effects, whereas its globular form with high molecular weight exhibits pro-inflammatory effects (25). The various adiponectin molecular species are differentially generated depending on in vivo physiological conditions, although no previous study has assessed the ratios between these three forms in patients with RA. These results indirectly indicate that inflammation may not be crucial for the modulation of the in vivo adipokine expression pattern of RA patients, and various unknown factors may be more involved in the modulation of in vivo adipokine expression. In order to evaluate the correlation between adipokine levels and resistance to treatment, pre-therapeutic serum adipokine levels were analyzed. As there was no statistically significant difference between non-responders and responders, it was concluded that pre-therapeutic adipokine levels do not contribute to resistance to treatment.

In conclusion, serum adipokine levels in RA patients were not significantly altered following therapy, with the exception of adiponectin. The results suggest that serum adipokine levels do not affect the degree of resistance to treatment and that serum adipokine levels in RA patients may be affected by various cell types and other unknown factors. Thus, it was hypothesized that in RA, serum adipokine levels do not reflect and have a limited effect on intraarticular inflammation.

Acknowledgements
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (grant nos. 2011-0026939 and 2011-0009061) and Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (grant no. A102065).

References